Palermo University, Italy
Forethinkers are those who can “imagine” and “see” results before working on them. Should you loose this, then better abandon research. (F, Marotta)
MD, Specialized in Gastroenterology, Fellow in gastroenterology at Chicago Univ. Nationwide-selected Registrar in gastroenterology, Univ. of Cape-Town, S. Africa under the pioneer prof. IN Marks. Holds the only European Japanese-spoken PhD (Hirosaki University, Japan) with pioneer work in pancreatology. Embassy-selected Fellow of Japanese Ministry of Science at Natl Cancer Center, Tokyo. Member of the Chinese Soc. of pancreatology, Molecular biology stage in London, Seoul. Hon. Research Professor at Dept of Nutrition, Texas W Univ., USA and Adjunt prof. at Nutrition dept, Sichuan University, China. Visiting prof. at major Asian universities. Has directed a research center in Japan for 10y and cooperated for 12y with Nobel Prof. Montagnier and Redox auhotiry prof. Packer. Advisory member of the CLS, Nazarbayev Univ. and Ministry of Science of Kazakhstan. Editor-board member of >35 intl. medical journals. Has received >10 international prizes (Japan Soc Hepatology 2002-5, Kumamoto Sci. Award 2004, Genomic Pioneer-2009 and Thomas Edison Award 2014-shared). Has co-edited 2 successful books on aging-intervention and >15 book chapters on Gut stem cells,probiotics, functional foods,nanotechnology and approaches for longevity promotion. Founder of ReGenera R&D International for Aging Intervention (the only EU-registered antiaging-related association in Italy) working on models of preventive/regenerative medicine cooperating as Chairman of the Foundation linked to VCC Medical Preventive Medicine Promotion, Beijing, China. At S. Babila Clinic – Vitality-CMB® Unit in Milano, Italy he pioneered integrated IV therapy, personalised BHRT and patented nutraceuticals. He has published >230 papers and presented >450 communications. International speaker at major universities and hospitals (Harvard, McGill, Osaka, Hasselt, Shanghai, Kobe, Kyoto, Tokyo, Kanazawa, Hiroshima, S.Diego, S.Barbara, Astana, Korea, Cairo etc.). Nominator for GI-related area for the Royal Canadian Society.
Strategic Scientific Consultant for Japanese, USA, EU drug and food supplements companies,
National Institute of Immunology, India.
My research interest has been emergent to develop translational disease intervention strategies against important human chronic diseases by cultivating the balance between tolerance versus immunity, abrogating inflammation, mediated by the gut microbiome. The project is based on the disruption of synchrony between the gut microbiome and metabolic rhythms by pathogenic infection.
United Biomedical, Asia (UBIA), Taiwan
Chang Yi Wang, founder, Chairperson and CSO of United Biomedical Asia (UBI Asia), is dedicated to discovery, development, and commercialization of immunotherapeutic vaccines and monoclonal antibodies for infectious diseases, allergies, and neurodegenerative disorders. She is passionate about delivering science-driven innovation with platform capabilities. In 1973, she was the first Asian woman accepted into Rockefeller University’s Ph.D. program., where she received training from, and worked with four, Nobel Laureates. Upon graduation she was head of Molecular Immunology laboratory at Sloan Kettering Institute She leveraged her research and management experience to establish UBI, with a strategy of keeping proprietary manufacturing technologies in-house. With UBI’s establishment Dr. Wang used designer peptides, proteins and monoclonal antibodies as the tool, combining her expertise in the field of immunology, virology and vaccinology for biomedical application in diagnostics, vaccines, and immunotherapeutics. Dr. Wang hash >140 peer-reviewed publications in prestigious journals (e.g. NEJM, Lancet, Science, J Exp Med, JCI, PLoS Pathogens etc)
All India Institute of Medical Sciences, India
Sampa Ghose, PhD, has been working as a research scientist for last 20 years after finishing her Ph.D. She is working as a Scientist in the department of Medical Oncology, All India Institute of Medical Sciences, New Delhi for past more than 5 years on role of EBV in Nesopharyngeal Carcinoma. She actively participates in different academic activities and faculty lecture series. After finishing her Ph.D, she has worked as a postdoctoral fellow in the department of Biochemistry at Medical University of South Carolina, USA and also worked as senior postdoctoral fellow in Vanderbilt Medical center, USA. During post doctoral studies she used to work on endothelial dysfunction towards angiogenesis and cancer metastasis. She has published her works in many peer reviewed international journals and presented her findings in many national and international symposium to her credit. She has recently published her findings, titled “Cell –free EBV as a biomarker during clinical management of nasopharyngeal carcinoma in a non-endemic region” in Journal of Medical Virology. She is life time member of several prestigious scientific communities like International Association of Cancer research (IACR), Indian society of Translational Research (ISTR) and Research and Education Society of Medical Oncology (RESMO).
Temple University, USA
Mark Feitelson received his Ph.D. in Microbiology and Immunology in 1979 from UCLA. He began his work with hepatitis B at Stanford University, and was then recruited to the Fox Chase Cancer Center by Dr. Baruch Blumberg (Nobel laureate). He has since worked on the pathogenesis of hepatitis B. In 1991, Dr. Feitelson moved to Thomas Jefferson University where he became Professor of Pathology and Cell Biology. He also was director of a Molecular Diagnostics Lab in Microbiology. In 2007, Dr. Feitelson went to Temple University as a Professor of Biology. His work has been supported by NIH, industry and foundations, has more than 150 publications, and 180 abstracts. He is also CSO of SFA Therapeutics. He has 14 patents, has mentored over 130 students.
Masuku University of Science and Technology, Franceville, Gabon
Leresche Even Doneilly OYABA YINDA is a PhD (Doctor) in Biomedical Sciences from the Ecole Doctorale (EDR) Régionale d’Afrique Centrale de Franceville, majoring in Biochemistry-Molecular Microbiology-Zoopharmacognosy. He obtained his bachelor’s degree in Biochemistry from the Université des Sciences et Techniques de Masuku (USTM), then his master’s degree from the same university, Franceville Gabon.
Ralstonia pickettii bloodstream infection in the patient with Guillain-Barre syndrome under plasmapheresis
Senior Drug Discovery & Medicinal Chemistry Pharmacist
Amgad Mohammed Rabie Hamed Fouda has completed his MSc and Postgraduate studies in Pharmaceutical and Biomedical Sciences at the age of 30 years from the Faculty of Pharmacy, Mansoura University, Egypt. He is one of the most famous and reputed Egyptian and Arab pharmacists, researchers and scientists. His new researches focused on the synthesis, discovery, and development of new drugs and medicines for the most resistant and untreated human diseases. He is the head of pharmacists at the Dikernis General Hospital (Mansoura, Egypt), a premier governmental hospital in Egypt. He has published more than 25 papers in very reputed journals and serving as an Editorial Board Member of great repute.
